[Corrigendum] MicroRNA‑506‑3p targets SIRT1 and suppresses AMPK pathway activation to promote hepatic steatosis
Affiliations: Department of Gastroenterology, Shidong Hospital, Shanghai 200438, P.R. China, Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, P.R. China
- Published online on: May 23, 2022 https://doi.org/10.3892/etm.2022.11390
- Article Number: 463
Copyright : © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Exp Ther Med 22:[Related article:] 1430, 2021; DOI: 10.3892/etm.2021.10865
Following the publication of this article, the authors regret that the paper contained some errors that should have been corrected before the article went to press. First, in the Materials and methods section, “miRNA transfection” subsection, on p. 2, right-hand column, line 6, the text “miR-505-3p mimics (5’-GGGAGCCAGGAACGAUUGAUGU-3’), inhib-itor (5’-ACUACUGAGCCGCAGUAGA-3’)” should have been written as “miR-506-3p mimics (5’-UAAGGCACCC-UUCUGAGUAGA-3’), inhibitor (5’-UCUACUCAGA-AGGGUGCCUUA-3’)”. Secondly, the authors have subsequently realized that certain of the primer sequences featured in Table I were written erroneously; specifically, the sequences for SREBP1, FASN, SCD1 and ACC1. A corrected version of Table I is shown opposite, where the proper sequences for SREBP1, FASN, SCD1 and ACC1 are shown, highlighted in bold.
The authors are grateful to the Editor of Experimental and Therapeutic Medicine for allowing them the opportunity to publish this corrigendum, and allt he authors agree with its publication. The authors also regret any inconvenience that this mistake has caused.